论文部分内容阅读
目的比较甘精胰岛素联合阿卡波糖治疗与预混胰岛素(诺和灵30R)治疗2型糖尿病合并冠心病的疗效与安全性。方法将94例2型糖尿病口服降糖药控制不能达标的患者随机分为两组.观察组为甘精胰岛素联合阿卡波糖;对照组为诺和灵30R组;两组以空腹血糖<7.0mmol/L,同时对照组晚餐前血糖<7.8mmol/L为目标;观察24周,观察血糖、低血糖的发生率、糖化血红蛋白及体重变化等指标。结果两组餐后血糖无统计学的差异;而空腹血糖、糖化血红蛋白的控制,夜间低血糖的发生率、体重增加均观察组优于对照组。结论甘精胰岛素联合阿卡波糖治疗口服降糖药物控制不佳的2型糖尿病合并冠心病的患者较诺和灵30R治疗,能较好的控制血糖、糖化血红蛋白且又可减少低血糖的发生,有良好的安全性。
Objective To compare the efficacy and safety of insulin glargine combined with acarbose and premixed insulin (noradren 30R) in the treatment of type 2 diabetes mellitus complicated with coronary heart disease. Methods 94 cases of type 2 diabetes oral hypoglycemic control can not meet the standard patients were randomly divided into two groups.The observation group was glargine combined with acarbose; control group was noradren 30R group; two groups with fasting blood glucose <7.0 mmol / L, while the control group before dinner, blood glucose <7.8mmol / L as the goal; observed for 24 weeks, observed the incidence of hypoglycemia, glycosylated hemoglobin and body weight changes and other indicators. Results There was no significant difference in postprandial blood glucose between the two groups. However, the fasting blood glucose, glycosylated hemoglobin, nighttime hypoglycemia and weight gain were better in the observation group than in the control group. Conclusion Glargine and acarbose treatment of patients with type 2 diabetes mellitus complicated with coronary heart disease who are not controlled by oral hypoglycemic drugs is better than noradren 30R treatment, which can control blood glucose, glycosylated hemoglobin and reduce hypoglycemia. , Have good safety.